Tycel Phillips, MD, discusses the role of targeted therapies in frontline mantel cell lymphoma (MCL) in this video interview with Blood Cancers Today.
Tycel Phillips, MD, on the Role of Targeted Therapies in Frontline MCL
By Leah Sherwood - Last Updated: February 1, 2023Post Tags:SOHO 2022
Related Posts
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
In the RELATIVITY-022 study, the combination's efficacy was greatest in Hodgkin lymphomas naive to PD-1 or PD-L1 inhibition.
Guest contributor Charles Gaulin, MBBS, outlines important updates on the first-line treatment of TP53-mutated MCL.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.